Blue Cross Blue Shield RI lymphedema policy Prior Auth

Coverage Criteria for Surgical Treatments

inv-01: Lymph Node Transplant

Lymph node transplant may be considered medically necessary when ALL of the following are met:

Lymph node transplant criteria: 1) Symptoms consistent with lymphedema as determined by a certified lymphedema therapist AND a diagnosis of ISL stage II lymphedema; 2) At least one positive quantitative measurement: volumetry differential (circumferential measurements and/or perometry) >10% if the affected extremity is the dominant extremity or >7% if the affected extremity is non-dominant; OR for unilateral disease lymphoscintigraphy demonstrating a minimum one-hour delayed transit time to first-level lymph nodes (axillary for upper extremity, inguinal for lower extremity) or a dermal backflow pattern; 3) Completion of a course of conservative lymphedema therapy defined as a minimum of 20 hours per week for 6 months, including compression therapy plus one or more of: complete decongestive therapy, manual lymphatic drainage, pneumatic compression pump, or targeted exercises, and demonstrated ability to tolerate post-surgical compression therapy and physical therapy sessions; 4) Body mass index (BMI) < 35 kg/m2; AND 5) NONE of the following exclusionary conditions: transient lymphedema occurring within 6 months of last oncologic treatment, lipedema without lymphatic dysfunction, venous disease (e.g., DVT, superior vena cava syndrome), medication-induced swelling, uncontrolled comorbidities (including congestive heart failure), nephropathy including end-stage renal disease, liver disease (including cirrhosis, hypoproteinemia), pregnancy, active infection of the affected extremity (cellulitis/erysipelas), dye anaphylaxis; surgical treatment to be performed by a hospital-credentialed, board-certified plastic surgeon.

inv-02: Lymphovenous Bypass

Lymphovenous bypass may be considered medically necessary when ALL of the following are met:

Lymphovenous bypass criteria: 1) Symptoms consistent with lymphedema as determined by a certified lymphedema therapist AND a diagnosis of ISL stage I lymphedema; 2) At least one positive quantitative measurement: volumetry differential >10% if affected extremity is dominant or >7% if non-dominant, OR bioimpedance (L-Dex) differential of at least 10 units, OR lymphoscintigraphy demonstrating a minimum one-hour delayed transit time to first-level lymph nodes or a dermal backflow pattern; 3) Indocyanine green (ICG) lymphangiography demonstrating presence of lymphatic channels; 4) Completion of a course of conservative lymphedema therapy defined as minimum 20 hours per week for 6 months (including compression therapy plus complete decongestive therapy, manual lymphatic drainage, pneumatic compression, or targeted exercises); 5) BMI < 35 kg/m2; AND 6) NONE of the following exclusionary conditions: transient lymphedema within 6 months post oncologic treatment, lipedema without lymphatic dysfunction, venous disease (e.g., DVT, superior vena cava syndrome), medication-induced swelling, congestive heart failure, liver disease, nephropathy including end-stage renal disease, pregnancy, dye anaphylaxis, active infection of the affected extremity; surgical treatment to be performed by a hospital-credentialed, board-certified plastic surgeon.

inv-03: Debulking of a Limb

Debulking of a limb may be considered medically necessary when ALL of the following are met:

Debulking criteria: 1) Signs and symptoms consistent with lymphedema as determined by a certified lymphedema therapist AND a diagnosis of ISL stage II lymphedema; 2) At least one positive quantitative measurement: volumetry differential >10% if affected extremity is dominant or >7% if non-dominant, OR bioimpedance (L-Dex) differential >=10 units, OR lymphoscintigraphy demonstrating a minimum one-hour delayed transit time to first-level lymph nodes or dermal backflow; 3) MRI imaging findings consistent with moderate to severe fat hypertrophy when applicable; 4) Completion of a course of conservative lymphedema therapy for a minimum of 6 months (including compression therapy plus complete decongestive therapy, manual lymphatic drainage, pneumatic compression, or targeted exercises) and demonstrated ability to tolerate post-surgical compression therapy and physical therapy sessions; 5) BMI < 35 kg/m2; AND 6) NONE of the following exclusionary conditions: transient lymphedema within 6 months post oncologic treatment, venous disease (e.g., DVT, superior vena cava syndrome), medication-induced swelling, congestive heart failure, liver disease (including cirrhosis, hypoproteinemia), nephropathy including end-stage renal disease, pregnancy, dye anaphylaxis, active infection of the affected extremity; surgical treatment to be performed by a hospital-credentialed, board-certified plastic surgeon.

inv-04: Lipedema - Liposuction/Excision/Debulking

Liposuction/excision/debulking for lipedema may be considered medically necessary when ALL of the following are met:

Lipedema surgical criteria: 1) Bilateral, symmetrical, disproportionate fatty tissue hypertrophy of the limbs documented with clinical records and photographs; AND diagnosis of lipedema with cuff phenomenon (feet/hands spared), absence of pitting edema unless comorbid lymphedema, pain or hypersensitivity in affected areas, negative Stemmer sign, AND documented significant functional impairment (e.g., difficulty ambulating, impaired ADLs, or recurrent cellulitis/skin ulcers); 2) Failure of adipose hypertrophy to respond to recommended bariatric surgery when applicable OR refractory to at least 6 months of conservative management (compression garments, complex decongestive therapy/manual lymph drainage, intermittent sequential pneumatic compression); 3) Evaluation by referring specialist (primary care/vascular/endocrine) confirming lipedema as independent cause of functional impairment and that surgery is expected to restore or improve function; 4) Surgical treatment performed by a hospital-credentialed, board-certified plastic surgeon; AND 5) When total aspirate is expected to exceed clinical standards (5000 cc) staging of liposuction may be necessary and procedures should be completed within a 12-month period when indicated.

inv-05: Surgical intervention medical necessity

Covered when ALL of the following are met

Initial criteria: Documented diagnosis of lymphedema or lipedema; conservative therapy attempted with inadequate response (e.g., >=6 months of decongestive therapy/compression) unless clinical circumstances justify earlier surgical interventionconservative therapy failure

Conservative therapy (compression, decongestive therapy) is the customary initial management for both lymphedema and lipedema.

Procedure-specific criteria: For debulking/liposuction: clinical documentation demonstrating symptomatic impairment (pain, mobility limitation), failure of conservative measures, and plan for staging when total aspirate >5,000 cc; For physiologic microsurgery (LVA, VLNT, LYMPHA): documentation of diagnosis, completion of prior conservative therapy, and surgical rationale (treatment vs prevention) providedprocedure-specific

Randomized evidence is limited for comparative efficacy of physiologic microsurgeries; specialist evaluation and clinical judgment required.

inv-06: Preventive lymphatic physiologic microsurgery (e.g., LYMPHA)

Preventive physiologic microsurgery (e.g., LYMPHA) during lymphadenectomy

Prevention criteria: Procedure may be considered when performed simultaneously with nodal dissection/reconstruction to attempt to reduce subsequent lymphedema incidence; existing randomized trials are small with limited follow-up and current evidence is insufficient to determine net health outcome (experimental/insufficient evidence).experimental/insufficient evidence

One RCT reported reduced incidence at 18 months but longer follow-up and higher-quality trials are needed.

The policy identifies several procedures as not covered / not medically necessary due to insufficient evidence: lymphatico-lymphatic bypass, vascularized lymph node transfer (VLNT), lymphaticovenular anastomosis, and lymphatic physiologic microsurgery performed during nodal dissection or breast reconstruction to prevent lymphedema (e.g., LYMPHA). The rationale provided is that the available evidence is insufficient to determine the effects of these technologies on health outcomes.

The policy states that for many physiologic microsurgeries the published evidence is dominated by single-arm series, heterogeneous techniques, and limited follow-up; randomized controlled trials are few and small. As a result, procedures lacking adequate comparative evidence cannot be concluded to improve the net health outcome compared with continued conservative therapy.

Services determined to be not medically necessary or identified as non-covered benefits are excluded from payment under this policy unless there is a prior written agreement with the member in which the member explicitly agrees to be responsible for charges.

The policy explicitly states that repeat liposuction in areas that have been fully treated is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products, because the evidence is insufficient to determine benefit from repeat procedures in previously treated areas.

Liposuction/excision/debulking for lipedema is only covered when all specified medical criteria are met (including documented bilateral symmetrical adipose hypertrophy, photographs, functional impairment, and failure of ≥6 months of conservative therapy). When those criteria are not met, liposuction for lipedema is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products.

The policy concludes there is insufficient evidence to determine that physiologic microsurgery procedures such as lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT) definitively improve net health outcomes compared with conservative treatment in many contexts. Single-arm series and small RCTs limit the ability to draw firm comparative conclusions; higher-quality randomized evidence with longer follow-up is needed.

The policy notes that some services may be determined to be not medically necessary based on the criteria and evidence review. Such services are not covered and may lead to claim denial unless the member has a prior written agreement accepting financial responsibility.

Coding — CPT, ICD-10 and Procedural Guidance

Procedures referenced as medically necessary or discussedmixed

No codes listed

Procedures listed as not covered / insufficient evidencemixedNot Covered

No codes listed

Liposuction staging guidancemixedCovered

>5000 cc	Total aspirate exceeds 5000 cc during the initial procedure — consider staging and completion within 12 months
≥5000 cc	Large-volume liposuction aspirate threshold; consider staging and perform in appropriate accredited facility

CPT Codes for Debulking / Unlisted lymphatic proceduresCPTCovered

15878	Suction assisted lipectomy; upper extremity
15879	Suction assisted lipectomy; lower extremity
38999	Unlisted procedure, hemic or lymphatic system

CPT Codes Medically Necessary when criteria metCPTCovered

15832	Excision, excessive skin and subcutaneous tissue (includes lipectomy); thigh
15833	Excision, excessive skin and subcutaneous tissue (includes lipectomy); leg
15834	Excision, excessive skin and subcutaneous tissue (includes lipectomy); hip
15835	Excision, excessive skin and subcutaneous tissue (includes lipectomy); buttock
15836	Excision, excessive skin and subcutaneous tissue (includes lipectomy); arm
15878	Suction assisted lipectomy; upper extremity
15879	Suction assisted lipectomy; lower extremity

ICD-10 CM Diagnosis Codes for Debulking of a limbICD-10

I89.0

Lymphedema, not elsewhere classified

No explicit CPT/ICD/HCPCS codes listed in this document segmentmixed

No codes listed

Volumetry differential thresholds

Volumetry differential (unilateral)>10% if the affected extremity is the dominant extremity; >7% if the affected extremity is non-dominant

Measurement methodsCircumferential measurements and/or perometry differential (used to calculate volumetry differential)

ApplicabilityRequired as at least one positive quantitative measurement for lymph node transplant, lymphovenous bypass, and debulking criteria for unilateral disease

Bioimpedance (L-Dex) differential

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for Medicare Advantage plans and recommended for Commercial products. Providers should confirm member-specific benefits and prior authorization requirements with the payer prior to scheduling or performing services.

Prior authorization required for Medicare Advantage Plans; recommended for Commercial Products.
Verify member benefits and prior authorization requirements with the payer before providing services.

Documentation Required

Conservative Therapy Prior to Surgery

Providers must document conservative therapy attempts before surgical consideration. Conservative therapy includes compression therapy (bandaging/garment/gauntlet) plus one or more of: complete decongestive therapy (CDT), manual lymphatic drainage (MLD), intermittent sequential pneumatic compression, targeted lymphedema exercises, or use of pneumatic compression devices. Documentation should include duration and frequency (e.g., a trial of conservative therapy for at least 6 months with specified hours/week when applicable) and the patient’s response.

Background and Evidence Summary

Background: Lymphedema is accumulation of lymphatic fluid caused by disruption of lymphatic drainage and may be primary or, more commonly, secondary. It can cause pain, risk of infection (eg, cellulitis), progressive limb enlargement, disfigurement, and functional impairment. Surgical interventions—ranging from physiologic microsurgery (eg, lymphovenous anastomosis, lymphovenous bypass, vascularized lymph node transfer) to debulking and suction-assisted lipectomy—are considered for patients who have persistent symptoms despite adequate conservative therapy. The clinical rationale for surgery is to reduce limb volume, decrease infection risk, and improve symptoms and function in appropriately selected patients.

Evidence sources for LVA: the policy references multiple systematic reviews, observational series, and randomized controlled trials. Reviews (and cited RCTs) highlight that much of the literature consists of single‑arm institutional series with variable techniques, outcomes metrics, and follow-up; a limited number of small RCTs exist, and larger, higher‑quality randomized trials are needed to establish comparative efficacy.

The policy cites guideline and position sources and longer-term outcome studies for liposuction/lipedema and lymph node transfer, including systematic reviews and position statements (for example, International Society of Lymphology guidance and National Lymphedema Network statements) and outcome series reporting multi‑year follow-up after liposuction and lymph node transfer procedures.

Key Definitions

Lymphedema — definition

DefinitionAccumulation of fluid due to disruption of lymphatic drainage

EtiologyMay be primary (congenital) or more commonly secondary (acquired) following lymphatic damage

Clinical consequencesLeads to pain, infection risk, disfigurement, and functional impairment

Lipedema — definition

DefinitionProgressive subcutaneous fat disorder causing disproportionate, bilateral fat overgrowth of the limbs and buttocks

Clinical featuresTypically spares hands/feet (cuff phenomenon), presents with pain, easy bruising, and disproportionate fat leading to mobility impairment

Policy Revision History

2024-08-01Effective

Policy became effective.

2025-09-03Next ReviewLatest

Scheduled next policy review date.

OpenPayer

Surgical Treatments for Lymphedema and Lipedema

Coverage Criteria for Surgical Treatments

Coding — CPT, ICD-10 and Procedural Guidance

Provider Actions, Prior Authorization, and Documentation

Background and Evidence Summary

Key Definitions

Policy Revision History